We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
3
Total approvals
Agencies
2
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
NMPA
National Medical Products Administration
1
FDA
Food and Drug Administration
- Real-world data shows belumosudil is often used in combination after multiple prior therapies for chronic graft-versus-host disease (cGVHD). - A retrospective study in Germany and Switzerland found a 42% overall response rate in patients with advanced cGVHD treated with belumosudil. - Belumosudil demonstrated a steroid-sparing effect and manageable safety profile in patients with severe cGVHD. - The ROCK2 inhibitor shows potential in earlier lines of cGVHD therapy, warranting further investigation in prospective trials.
